233 related articles for article (PubMed ID: 25336073)
1. Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.
Ghosh AK; Yashchuk S; Mizuno A; Chakraborty N; Agniswamy J; Wang YF; Aoki M; Gomez PM; Amano M; Weber IT; Mitsuya H
ChemMedChem; 2015 Jan; 10(1):107-15. PubMed ID: 25336073
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
[TBL] [Abstract][Full Text] [Related]
3. Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.
Ghosh AK; Martyr CD; Osswald HL; Sheri VR; Kassekert LA; Chen S; Agniswamy J; Wang YF; Hayashi H; Aoki M; Weber IT; Mitsuya H
J Med Chem; 2015 Sep; 58(17):6994-7006. PubMed ID: 26306007
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
Ghosh AK; Kovela S; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
J Med Chem; 2020 May; 63(9):4867-4879. PubMed ID: 32348139
[TBL] [Abstract][Full Text] [Related]
5. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
[TBL] [Abstract][Full Text] [Related]
6. Design of Highly Potent, Dual-Acting and Central-Nervous-System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants.
Ghosh AK; Rao KV; Nyalapatla PR; Kovela S; Brindisi M; Osswald HL; Sekhara Reddy B; Agniswamy J; Wang YF; Aoki M; Hattori SI; Weber IT; Mitsuya H
ChemMedChem; 2018 Apr; 13(8):803-815. PubMed ID: 29437300
[TBL] [Abstract][Full Text] [Related]
7. Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.
Ghosh AK; Chapsal BD; Steffey M; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2012 Mar; 22(6):2308-11. PubMed ID: 22364812
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.
Ghosh AK; Yu X; Osswald HL; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
J Med Chem; 2015 Jul; 58(13):5334-43. PubMed ID: 26107245
[TBL] [Abstract][Full Text] [Related]
9. Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.
Ghosh AK; Chapsal BD; Parham GL; Steffey M; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
J Med Chem; 2011 Aug; 54(16):5890-901. PubMed ID: 21800876
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands.
Ghosh AK; Martyr CD; Kassekert LA; Nyalapatla PR; Steffey M; Agniswamy J; Wang YF; Weber IT; Amano M; Mitsuya H
Org Biomol Chem; 2015 Dec; 13(48):11607-21. PubMed ID: 26462551
[TBL] [Abstract][Full Text] [Related]
11. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
Ghosh AK; Gemma S; Takayama J; Baldridge A; Leshchenko-Yashchuk S; Miller HB; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
Org Biomol Chem; 2008 Oct; 6(20):3703-13. PubMed ID: 18843400
[TBL] [Abstract][Full Text] [Related]
12. Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.
Rusere LN; Lockbaum GJ; Henes M; Lee SK; Spielvogel E; Rao DN; Kosovrasti K; Nalivaika EA; Swanstrom R; Kurt Yilmaz N; Schiffer CA; Ali A
J Med Chem; 2020 Aug; 63(15):8296-8313. PubMed ID: 32672965
[TBL] [Abstract][Full Text] [Related]
13. Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
Ghosh AK; R Nyalapatla P; Kovela S; Rao KV; Brindisi M; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
J Med Chem; 2018 May; 61(10):4561-4577. PubMed ID: 29763303
[TBL] [Abstract][Full Text] [Related]
14. A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.
Yedidi RS; Garimella H; Aoki M; Aoki-Ogata H; Desai DV; Chang SB; Davis DA; Fyvie WS; Kaufman JD; Smith DW; Das D; Wingfield PT; Maeda K; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2014 Jul; 58(7):3679-88. PubMed ID: 24752271
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.
Ghosh AK; Fyvie WS; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
ChemMedChem; 2017 Dec; 12(23):1942-1952. PubMed ID: 29110408
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
Ghosh AK; Sridhar PR; Leshchenko S; Hussain AK; Li J; Kovalevsky AY; Walters DE; Wedekind JE; Grum-Tokars V; Das D; Koh Y; Maeda K; Gatanaga H; Weber IT; Mitsuya H
J Med Chem; 2006 Aug; 49(17):5252-61. PubMed ID: 16913714
[TBL] [Abstract][Full Text] [Related]
17. Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.
Ghosh AK; Xia Z; Kovela S; Robinson WL; Johnson ME; Kneller DW; Wang YF; Aoki M; Takamatsu Y; Weber IT; Mitsuya H
ChemMedChem; 2019 Nov; 14(21):1863-1872. PubMed ID: 31549492
[TBL] [Abstract][Full Text] [Related]
18. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
Ghosh AK; Gemma S; Baldridge A; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
J Med Chem; 2008 Oct; 51(19):6021-33. PubMed ID: 18783203
[TBL] [Abstract][Full Text] [Related]
19. Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
Ghosh AK; Rao KV; Nyalapatla PR; Osswald HL; Martyr CD; Aoki M; Hayashi H; Agniswamy J; Wang YF; Bulut H; Das D; Weber IT; Mitsuya H
J Med Chem; 2017 May; 60(10):4267-4278. PubMed ID: 28418652
[TBL] [Abstract][Full Text] [Related]
20. Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.
Ghosh AK; Williams JN; Ho RY; Simpson HM; Hattori SI; Hayashi H; Agniswamy J; Wang YF; Weber IT; Mitsuya H
J Med Chem; 2018 Nov; 61(21):9722-9737. PubMed ID: 30354121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]